Tiancong officially launches the CKBA drug treatment for Alzheimer's disease adaptation research and development.

Taencon announced today the official launch of the development of innovative drug CKBA 1.1 for the treatment of Alzheimer's disease. Zheng Hanjie, Chairman of the company, told reporters that while Taencon is accelerating the research and development progress of AD indications, it will also steadily advance the phase III clinical preparation and drug application for CKBA in vitiligo, as well as the phase II/III clinical trials for acne rosacea indications. For some indications, the company has already begun to establish business units in order to accelerate the commercialization process after approval. In addition, the company's existing products and multiple generic drugs that are expected to be approved soon are expected to provide stable cash flow for the company's innovative drug research and development. The innovative research results of Taencon's CKBA for AD treatment recently appeared in the top international journal "Nature Aging". This research not only reveals the key targets of the early metabolic inflammation coupling pathway of AD, but also confirms the development potential of CKBA as a new generation of small molecule candidate drug targeting immune metabolism from natural sources, demonstrating a complete chain from mechanism research to translational application.